ACAnne Marie Comi

Anne Marie Comi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Anne Marie Comi has a total of 268 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vocational and Educational Outcomes in Adults With Sturge–Weber Syndrome: Preliminary Results From a Clinical Needs Assessment

    by Katharine E. Joslyn, Catherine Stephan, Anne M. Comi, Andrew T. Zabel

    Objective: The clinical presentation of Sturge–Weber syndrome (SWS) is highly variable, with seizures during infancy and co‑occurring neurodevelopmental conditions commonly reported. Although these features are known to affect childhood functioning, their relationship to adult vocational and educational outcomes remains poorly understood. This study examined the impact of early seizure history, self‐reported current cognitive and social difficulties, and current adult neurological functioning—as measured by the Sturge–Weber Syndrome Neurological Rating Scale (SWS‑NRS) on vocational and educational outcomes in adults with SWS. Methods: A cross‑sectional, web‑based clinical needs assessment incorporating the Vocational and Educational Index (VEI) was distributed to all adults with SWS seen at our center since 2019 ( N = 59). Twenty research‐consented participants responded and were included in the data analysis (34% response rate). Results: Higher VEI scores were strongly associated with better (lower) SWS‑NRS ( r s = −0.71, p < 0.001), and post hoc analysis revealed an association between hemiparesis and lower VEI score. Moreover, the presence of one or more self‑reported current cognitive or social difficulties was associated with poorer vocational and educational outcomes ( p = 0.003). Conclusions: These preliminary findings suggest that adult neurological functioning and co‑occurring cognitive or social concerns are important correlates of vocational and educational outcomes in adults with SWS. Early identification and longitudinal monitoring of neurodevelopmental comorbidities (particularly for individuals with both SWS and hemiparesis) may inform targeted interventions and transition planning. Larger studies are needed to further clarify predictors of adult functional outcomes in this rare population.

  • Open Access

    Steroids for Drug‐Resistant Seizures and Prolonged Stroke‐Like Episode in a Patient With Sturge–Weber Syndrome: A Case Report

    by Brenna N. Keam, Fabiola A. Morales‐Vias, Siddharth S. Gupta, Doris D. Lin, Anne M. Comi

    Introduction: Sturge–Weber syndrome (SWS) brain involvement has been associated with impairments in the blood–brain barrier (BBB) and microglial activation within involved cortical regions. Acute neurological crises, including seizures, stroke‐like episodes, and/or significant headaches, are common in these patients. This report describes in detail an adolescent with SWS and acute drug‐resistant status epilepticus, headache, and stroke‐like episode who improved clinically when treated with high‐dose steroids. Review of medical records identified two other patients previously treated with steroids for acute neurological symptoms. Case Presentation: A 13‐year‐old boy with SWS brain involvement presented with fever, headache, seizures, and right‐sided weakness. Brain magnetic resonance imaging (MRI) revealed characteristic findings of SWS. The patient was placed on continuous electroencephalogram that showed findings consistent with electrographic status epilepticus. Seizures were refractory to multiple anti‐seizure medications as well as to an intravenous midazolam drip. A repeat MRI of the brain documented a significant increase in leptomeningeal enhancement with associated gyral edema and sulcal effacement. Steroid therapy with methylprednisolone and prednisone improved his status epilepticus and stroke‐like symptoms, including resolution of seizures and marked improvement in his hemiparesis. Conclusion: This patient suggests a potential role for inflammation‐targeted therapies in individuals with SWS brain involvement who present with prolonged neurological crises. Two other patients with SWS brain involvement who were treated with high‐dose steroids in the context of acute neurological episodes also support the need for future clinical and preclinical research to validate this approach.

  • Open Access

    In Vitro Models of Sturge–Weber Syndrome: Strengths, Limitations, and Future Goals

    by Ashleigh B. Manney, Christina L. Nemeth, Anne M. Comi

    Sturge–Weber Syndrome (SWS) is a rare congenital disorder presenting with a vascular malformation in the upper face and brain, causing impaired blood–brain barrier function and perfusion, increased calcium signaling, inflammation, and seizures. All these neuropathologic processes result in injury to the brain. The somatic GNAQ R183Q variant, which accounts for the majority of SWS cases, increases signaling through MAPK, PI3K, mTOR, and inflammatory pathways, primarily in endothelial cells. The discovery of this variant enabled the creation of transgenic and genetic animal and cell culture models. Generating in vitro models has been challenging due to the mosaic nature of SWS, and attempts to separate unaffected from mutant cells in primary culture have failed, limiting the utility of in vitro work. Ongoing in vitro work seeks to overcome these limitations, shape our understanding of SWS, and lead to translational advances in treatment and prevention by studying the affected molecular pathways and identifying future targets for therapy.

  • Open Access

    Acute Seizure Susceptibility and Chronic Vascular Malformation in a Developmental Mouse Model of Sturge–Weber Syndrome

    by Nicholas Truver, Chase Solomon, Anne Comi

    Sturge–Weber Syndrome (SWS) is a rare neurovascular disorder caused by a somatic mosaic missense point mutation in GNAQ, resulting in a facial capillary malformation (port-wine birthmark) and abnormal blood vessels in the eye and brain. Symptoms include seizures, stroke-like episodes, and glaucoma. Acute seizures induced with low-dose kainate in a transgenic GNAQ R183Q mouse model of SWS assessed seizure susceptibility and the impact of seizures on cerebral vasculature. Mice expressing human GNAQ mutation experienced more severe seizures and greater seizure-induced mortality compared to littermate controls. Mutant mice had longer cortical microvessels, with larger diameters; the expression of tight junction proteins was reduced 2 days after seizures. Blood–brain barrier permeability was not different from controls after chronic gene expression, although vascular dilation persisted compared to controls. These data demonstrate increased seizure susceptibility in this somatic mosaic model of SWS, bidirectional interactions between seizure and vascular remodeling, and chronic persistence of vascular malformation.

  • Open Access

    Biomarker development in Sturge-Weber syndrome

    by Siddharth S. Gupta, Katharine E. Joslyn, Kieran D. McKenney, Anne M. Comi

    Sturge-Weber Syndrome (SWS) is a congenital neurovascular disorder caused by a somatic mosaic mutation in the R183Q GNAQ gene and characterized by capillary-venous malformations of the brain, skin, and eyes. Clinical manifestations include facial port-wine birthmark, glaucoma, seizures, headache or migraine, hemiparesis, stroke or stroke-like episodes, developmental delay, behavioral problems, and hormonal deficiencies. SWS requires careful monitoring, management, and early identification to improve outcome and prevent neurological deterioration. Over the last 25 years, biomarkers have been developed to improve early diagnosis and prognosis and allow for the monitoring of clinical status and treatment response. Importantly, advancements in biomarker research may enable presymptomatic treatment for infants with SWS. This review summarizes current, ongoing, and potential future SWS biomarker studies. These biomarkers, in combination with clinical data, offer a rich source of data for rare disease research leveraging machine learning in future research.


  • Open Access

    Sturge–Weber syndrome: updates in translational neurology

    by Chase Solomon, Anne Comi

    Sturge–Weber syndrome (SWS) is a rare congenital neurovascular disorder that initially presents with a facial port-wine birthmark (PWB) and most commonly associated with a R183Q somatic mosaic mutation in the gene GNAQ. This mutation is enriched in endothelial cells. Contrast-enhanced magnetic resonance imaging (MRI) diagnoses brain abnormalities including leptomeningeal vascular malformation, an enlarged choroid plexus, and abnormal cortical and subcortical blood vessels. Mouse SWS models identify dysregulated proteins important for abnormal vasculogenesis and blood brain barrier permeability. Recent clinical research has focused on early diagnosis, biomarker development, presymptomatic treatment, and development of novel treatment strategies. Prospective pilot clinical drug trials with cannabidiol (Epidiolex) or with sirolimus, an mTOR inhibitor, indicate possible reductions in seizure frequency and improved cognitive outcome. This review connects the most recent molecular research in SWS cell culture and animal models to developing new treatment methods and identifies future areas of research.


  • Open Access

    A Review of Sturge–Weber Syndrome Brain Involvement, Cannabidiol Treatment and Molecular Pathways

    by Katharine Elizabeth Joslyn, Nicholas Flinn Truver, Anne Marie Comi

    Sturge–Weber syndrome (SWS) is a rare congenital neurocutaneous disorder typically caused by a somatic mosaic mutation in R183Q GNAQ. At-risk children present at birth with a capillary malformation port-wine birthmark. The primary diagnostic characteristic of the disorder includes leptomeningeal enhancement of the brain, which demonstrates abnormal blood vessels and results in impaired venous drainage and impaired local cerebral perfusion. Impaired cerebral blood flow is complicated by seizures resulting in strokes, hemiparesis and visual field deficits, hormonal deficiencies, behavioral impairments, and intellectual disability. Therefore, anti-seizure medication in combination with low-dose aspirin is a common therapeutic treatment strategy. Recently published data indicate that the underlying mutation in endothelial cells results in the hyperactivation of downstream pathways and impairment of the blood–brain barrier. Cannabidiol (CBD) has been used to treat medically refractory seizures in SWS due to its anti-seizure, anti-inflammatory, and neuroprotective properties. Pilot research suggests that CBD improves cognitive impairment, emotional regulation, and quality of life in patients with SWS. Recent preclinical studies also suggest overlapping molecular pathways in SWS and in CBD, suggesting that CBD may be uniquely effective for SWS brain involvement. This review aims to summarize early data on CBD’s efficacy for preventing and treating epilepsy and neuro-cognitive impairments in patients with SWS, likely molecular pathways impacted, and provide insights for future translational research to improve clinical treatment for patients with SWS.


  • Open Access

    Paternal, Maternal, and Familial Factors as Predictors of Sturge–Weber Syndrome Neurological Outcome

    by Kieran D. McKenney, Andrew T. Zabel, Jayda M. Harris, Anne M. Comi

    Objectives: To identify potential risk factors influencing Sturge–Weber Syndrome (SWS) and neurological outcomes in individuals with SWS and port-wine birthmarks from paternal, maternal, and familial factors. Methods: This study follows a retrospective cross-sectional design. Clinical visits took place at the Kennedy Krieger Institute, a tertiary care center. Participants were individuals with SWS or port-wine birthmarks. Results: Higher paternal age at conception was associated with a range of cognitive dysfunctions in offspring with SWS brain involvement. Indeed, paternal age was associated with low intelligence quotient (n = 25, P = .004), strokes or stroke-like episodes (n = 34, P = .030), gross and/or fine motor delay (n = 34, P = .036), delays in ability to perform activities of daily living (n = 30, P = .012), and delayed learning compared to peers (n = 31, P = .027). Furthermore, paternal age was correlated with worse cognitive outcomes, as measured by cognitive Neuroscore (r s = 0.575, P < .001, n = 32). When maternal thyroid disease and hypertension were present during pregnancy, offspring were more likely to experience low intelligence quotient (n = 30, P = .041) and regression of any abilities (n = 37, P = .045), respectively. Logistic regression confirmed the association between paternal age and severe cognitive Neuroscore (β = .580, P = .033, odds ratio: 1.79, 95% confidence interval: 1.05–3.04), even when controlling for the effects of seizures and strokes or stroke-like episodes. Conclusions: Prenatal factors were associated with neurological symptoms in subjects with SWS. Older paternal age, in particular, may predict worse neurocognitive outcomes. Further research is needed in larger cohorts to determine the value of the identified prenatal factors as prognostic tools. Likewise, animal models may be used to determine the impact of prenatal factors on the severity of outcome.

  • Open Access

    R183Q GNAQ Sturge–Weber Syndrome Leptomeningeal and Cerebrovascular Developmental Mouse Model

    by Chase Solomon, Meghan McCann, Pratibha Singh, Christina Nemeth, Anne Comi

    Objective(s): Sturge–Weber syndrome (SWS), a rare neurovascular malformation disorder, is usually caused by the R183Q GNAQ somatic mosaic mutation enriched in brain endothelial cells. A developmental mouse model of SWS brain involvement is needed to investigate mutation impact upon brain vascular development and to facilitate preclinical drug studies. Methods: A new Tet-ON R183Q GNAQ transgenic mouse line was paired with rtTA tet transactivator mice under the Tie2 promoter to generate mice expressing endothelial R183Q GNAQ in the presence of doxycycline. Litters were perfused at P14-17; half received a subseizure dose (1.5 mg/kg; intraperitoneal) of kainate an hour before perfusion. A subset was perfused with Evans blue. Fixed mouse brains were stained with X-gal, DAPI, and antibodies for Gαq, Tie2, phosphorylated-S6, and claudin-5. Images were scored for vessel staining intensity. Results: X-gal staining was seen only in mutant mice; leptomeningeal endothelial X-gal staining was more frequent in kainate-treated mice (P < 0.001). When perfused with Evans blue, only mutant brains showed severe staining (P = 0.028). Median phosphorylated-S6 vessel scores were significantly higher in the leptomeninges of mutant mice (P = 0.035). Mutant cortical microvessels demonstrated discontinuous claudin-5 and phosphorylated-S6 staining as well as increased vessel length in kainate-treated mice (P = 0.024). Conclusions: The new R183Q GNAQ Tet-ON developmental mouse brain model of SWS demonstrates endothelial expression of mutant Gαq associated with blood–brain barrier breakdown, altered vascular mammalian target of rapamycin activity, and abnormal cortical microvessel structure. This new translational model can be used to develop new drug targets and treatments for SWS.


  • Time to change our approach to presymptomatic treatment of Sturge–Weber syndrome

    by Anne M. Comi

    This commentary is on the original article by Mankel et al. on pages 111–118 of this issue.